David Berg, M.S., was the Director and Cofounder, with Lois Hill Berg, of HEMEX Laboratories before he retired and sold it. He was a medical technologist with a graduate degree in clinical pathology and laboratory medicine, who specialized in the hypercoagulation of blood in infertility, as well as, CFS, fibromyalgia, and Gulf War Illness.
Berg and Joseph Brewer studied coagulation in CFS patients and concluded that approximately 85% of chronic fatigue syndrome patients had hypercoagulation, i.e., the tendency for blood to clot too much, possibly from lower serum levels. He reported that a significant percentage of people obtain remission from anti-coagulation therapy combined with anti-infection therapy.
Talks and interviews[edit | edit source]
- 1998, Treatment protocol
- 1999, 1999 AHMF Meeting
- Aug 29, 1999, Radio Interview Transcript
- 2007, Interview with David Berg - Hypercoagulation Linked to Chronic Fatigue, Fibromyalgia, MS, Infertility, Chronic Illness
- 2012, Town Hall Talk #1
- 2012 Town Hall Talk #3
- 2012, Town Hall Talk #4
Notable studies[edit | edit source]
- 2001, Hypercoaguable State Associated with Active Human Herpesvirus-6 (HHV-6) Viremia in Patients with Chronic Fatigue Syndrome - (Abstract)
References[edit | edit source]
- Joseph Brewer & David Berg. (2001). Hypercoaguable State Associated with Active Human Herpesvirus-6 (HHV-6) Viremia in Patients with Chronic Fatigue Syndrome. Journal of Chronic Fatigue Syndrome, Vol. 8, Iss. 3-4, pp. 111-116. http://dx.doi.org/10.1300/J092v08n03_10
- Brewer, Joseph H.; Berg, David (January 2001). "Hypercoaguable State Associated with Active Human Herpesvirus-6 (HHV-6) Viremia in Patients with Chronic Fatigue Syndrome". Journal of Chronic Fatigue Syndrome. 8 (3–4): 111–116. doi:10.1300/J092v08n03_10. ISSN 1057-3321.